AUS
NZ
UK
CA
USA
IND
Imugene Limited (ASX:IMU) has released its half-year results ended 31 December 2018. As at 31 December 2018, the group recorded a loss for half-year $3,449,097 (2017: $1,632,852). The loss in the business from the comparative period was caused by the major rise in the clinical experiments and research work managed by the company.
Financial Performance:
In July 2018 $20.1 million capital before costs were raised by the company. Its net assets on 31 December 2018 stood at $31,189,570 than $15,475,479 on 30 June 2018. The cash reserves of the company on 31 December 2018 stood at $24,053,140 than $7,822,057 on 30 June 2018.
The Net cash outflow from operating activities on 31 December 2018 stood at $2,791,701 from $916,769 in the previous corresponding period (PCP). The Net cash inflow from investing was activities by the end of HY 2019 was $ 100,067 from $ 17,495 in the PCP. The Net cash inflow from financing activities by the end of HY 2019 was $ 18,801,176 from $8,002,308 in PCP. The Cash and cash equivalents as on 31 December 2018 stood at $ 24,053,140 compared to 11,923,686 in PCP.
Dividend:
For the present fiscal period, no dividends had been paid or declared by the company.
Business Performance:
HER-Vaxx
The companyâs stage 1b/2 clinical test had been aiming toward patients who suffer from HER-2 positive gastric cancer in Asia and Eastern Europe zones.
Ohio State University/Mayo Clinic licences
On 7 June 2018, IMU notified that the company had signed a global licence to the complete body of cancer vaccine work and intellectual property, evolved by professor of The Ohio State University Wexner Medical Center and The Comprehensive Cancer Center â A.G.J Cancer Hospital and R. J.R Institute and Mayo Clinic.
B-VAXX
The stage 1b/2 test with B-Vaxx has concluded stage 1b, and stage 2 work has already begun.
PD-1 B-cell peptide cancer vaccine known as âKEY-Vaxxâ
The pre-clinical trials and study on toxicology had already started by the company. The clinical test groundwork is going on, and the team had concluded a meeting with the FDA to converse about pre-clinical and study on toxicology.
On 23 August last year, the company notified that it had appointed Dr Mark T. Marino as its Chief Medical Officer.
Outlook:
The companyâs objective for short to medium period would be aimed at the stage 1b/2 gastric cancer study design which comprises of HER-Vaxx: recruitment of phase 2 trial with gastric cancer patients, KEY-Vaxx would quicken pre-clinical studies, attain an IND âgoâ and begin the clinical trial.
Further, the companyâs securities pressed a pause button on ASX today pending further announcement.
IMU has also updated the market today that Professor U. Wiedermann who is also a co-inventor of HER-Vaxx, would give a presentation about HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 yearly meeting planned from 29 March-3 April 2019, in Atlanta, Georgia.
About the presentation
The abstract presentation had been written by Prof Wiedermann and researchers at the Medical University of Vienna in Austria and IMU.
The abstract presentation had been entitled âA Phase Ib open-label multicentre study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced cancer of the stomach.â
Recently, the company has notified that the Phase 1 clinical trial data for its B cell peptide cancer vaccine B-Vaxx was printed in the reputable American Association for Cancer Research journal Clinical Cancer Research.
Stock Performance:
The stock of the company last traded at A$0.020 (as at 28 February 2019), up by 17.647% from its previous close.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
